Search Saint Luke's

Long before breakthroughs can happen in our hospitals, they must start in the hearts of kind and generous people like you. As a not-for-profit organization, Saint Luke’s relies on our supporters to partner with as we work hard to make a difference in the field of health care.

The Emergency Medicine rotation will provide students exposure and opportunity to participate in the essential roles of the pharmacist in the Emergency Department through the activities outlined below.

The intent of these exchanges is to provide caregivers with secure access to patient health information so they can render the most effective care regardless of where the patient seeks that care.

Colorectal cancer is often called a "silent cancer" because there aren't always symptoms until the cancer is advanced. The cancer is preventable, and screenings can help catch it early when it's more treatable.

Radiographers are vital members of the health care team, gathering and analyzing information that assists in diagnosis and treatment of disease. Saint Luke’s nationally accredited School of Radiologic Technology offers a two-year, hospital-based program to prepare students for a successful career in radiography.

The Medication Safety rotation is a one-month rotation designed to provide students with a broad perspective of medication safety topics and activities in a health-system. It will build on the student’s basic clinical knowledge and understanding of pharmacy operations and will enhance the student’s critical thinking skills.

A primary goal of the BJC ACO is to improve the quality of care our patients receive under the program. We want to help patients stay healthier, and that means improving our care standards and changing the ways we deliver those services to our patients.

Meet Pat Patton, leader of Allen and Anderson County Hospitals, delivering expert, patient-centered care with Saint Luke's commitment to your health. Learn more.

The abdominal transplant clinic rotation involves the provision of pharmaceutical care for patients under the kidney and liver transplant teams.

Breast Cancer
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment